Literatura na postawie której powstaje strona:

Selamaj „Stawardnienie rozsiane”, Termedia, 2013

Blackstone, Stwardnienie rozsiane. Przyczyny choroby, objawy, metody leczenia. Poradnik dla chorych i ich rodzin, Klub Dla Ciebie, Warszawa 2007

„Herbs and Nutrients for Neurologic Disorders, Tretment Strategies for Alzheimer’s, Stroke, Multiple Sclerosis, Migrene and Seizures” Sidnay J. Kum M.D.; Sheryl Shook, Ph.D.

„Managing Multiple Sclerosis Naturally A self-help Giude to Living with MS” Judy Graham

Stwardnienie Rozsiane Chris H. Polman Alan J. Thompson T. Jock Murray Allen C. Bowling John H. Noseworthy red. wyd. pol. Jerzy Kotowicz  Warszawa 2011, wyd.1

Chainani-Wu, N. 2003. Safety and anti-inflammatory activity of curcumin: A component of tumeric (Curcuma longa). J Altern Complement Med 9 (1): 161–68.

Leu, T. H, and M. C. Maa. 2002. The molecular mechanisms for the antitumorigenic effect of curcumin. Curr Med Chem Anti-Canc Agents 2 (3): 357–70.

Packer, L., et al. 1997. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 22 (1–2): 359–78.

Packer, L. 1998. Alpha-lipoic acid: A metabolic antioxidant which regulates NF-kappa-B signal transduction and protects against oxidative injury. Drug Metab Rev 30 (2): 245–75.

Martinelli Boneschi, F., et al. 2003. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: Meta-analysis of three double-blind, randomized, placebo-controlled

DeLuca, G. C., et al. 2006. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 129 (Pt 6): 1507–16.

Andrews, H. E., et al. 2005. Mitochondrial dysfunction plays a key role in progressive axonal loss in multiple sclerosis. Med Hypothesis 64 (4): 669–77

Swank, R. L. 1950. Multiple sclerosis: A correlation of its incidence with dietary fat. Am J Med Sci 220 (4): 421–30.

Swank, R. L., et al. 1952. Multiple sclerosis in rural Norway its geographic and occupational incidence in relation to nutrition. N Engl J Med 246 (19): 722–28.

Nordvik, I., et al. 2000. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand 102 (3): 143–49.

Sinclair, H. M. 1956. Deficiency of essential fatty acids and atherosclerosis, etcetera. Lancet 270 (6919): 381–83.

Frequin, S. T., et al. 1993. Decreased vitamin B 12 and folate levels in cerebrospinal fluid and serum of multiple sclerosis patients after high-dose intravenous methylprednisolone. J Neurol 240 (5): 305–8.

Sandyk, R., and G. I. Awerbuch. 1993. Vitamin B 12 and its relationship to age of onset of multiple sclerosis. Int J Neurosci 71 (1–4): 93–99.

Reynolds, E. H. 1992. Multiple sclerosis and vitamin B 12 metabolism. J Neuroimmunol 40 (2–3): 225–30.

Kira, J., et al. 1994. Vitamin B 12 metabolism and massive-dose methyl vitamin B 12 therapy in Japanese patients with multiple sclerosis. Intern Med 33 (2): 82–86

Ashton Embry, “Vitamin D Supplementation in the Fight Against MS,” www.msr­­ads/bbd_Vitami­n_D_update_GP_L­etter-4.pdf (accessed April 19, 2010); John N. Hathcock, Andrew Shao, Reinhold Vieth, et al. “Risk Assessment for Vitamin D,” The American Journal of Clinical Nutrition 85, no. 1 (January 2007): 6–18

F. van der Mei, A. Ponsonby, L. Blizzard, et al., “Regional Variation in Multiple Sclerosis Prevalence in Australia and Its Association with Ambient Ultraviolet Radiation,” Neuroepidemiology 20 (2001): 168–74, doi: 10.1159/000054783

A. Woolmore, “Studies of Associations Between Disability in Multiple Sclerosis, Skin Type, Gender, and Ultraviolet Radiation,” Multiple Sclerosis Journal 13, no. 3 (2007): 369–75.

V. Ramagopalan, N. J. Maugeri, L. Handunnetthi, et al., “Expression of the Multiple Sclerosis-associated MHC Class II Allele HLA-DRB1*1501 Is Regulated by Vitamin D,” PLoS Genetics 5, no. 2 (2009): e1000369, doi:10.1371/ journal.pgen.1000369.

Christakos, “Vitamin D May Protect against MS,” Journal of Cellular Biochemistry 105, no. 2 (2008): 338–43.

Holmoy, “Vitamin D Status Modulates the Immune Response to Epstein Barr Virus: Synergistic Effect of Risk Factors in Multiple Sclerosis,” Medical Hypotheses 70, no. 1 (2008): 66–69.

A. van der Mei et al., “Vitamin D Levels in People with Multiple Sclerosis and Community Controls in Tasmania, Australia,” American Journal of Neurology 254, no. 5 (May 2007): 581–90

T. Kampmann and M. Brustad, “Vitamin D: A Candidate for the Environmental Effect in Multiple Sclerosis—Observations from Norway,” Neuroepidemiology 30, no. 3 (2008): 140–46

C. Ebers, A. D. Sadovnick, R. Vieth, et al., “Vitamin D Intake and Incidence of Multiple Sclerosis,” Neurology 63, no. 5 (September 2004): 939.

L. Munger, L. I. Levin, B. W. Hollis, et al., “Serum 25-hydroxyvitamin D Levels and Risk of Multiple Sclerosis,” Journal of the American Medical Association 296 (2006): 2832–38.

L. Munger, S. M. Zhang, E. O’Reilly, et al., “Vitamin D Intake and Incidence of Multiple Sclerosis,” Neurology 62, no. 1 (2004): 60–65.

Vieth, “Vitamin D Supplementation, 25-hydroxyvitamin D Concentrations, and Safety,” American Journal of Clinical Nutrition 69, no. 5 (May 1999): 842–56.

Margheritia T. Cantora, “Vitamin D and Autoimmunity: Is Vitamin D Status an Environmental Factor Affecting Autoimmune Disease Prevalence?” Experimental Biology and Medicine 223, no. 3 (2000): 230–33.

F. Holick, “Sunlight and Vitamin D for Bone Health and Prevention of Autoimmune Diseases, Cancers, and Cardiovascular Disease,” American Journal of Clinical Nutrition 80 (December 2004): 1678S–88S.

strony www: